Why Did Novo Stock Fall So Sharply YesterdayNovo Nordisk shares plunged nearly 20–23% on July 29, 2025, marking its worst trading day since Black Monday in 1987.
Significant Downgrade of 2025 Financial Outlook
The company revised its sales growth forecast for 2025 down to 8–14%, from its prior guidance of 13–21%, and reduced expected operati
Key facts today
Novo Nordisk's stock surged after data showed its diabetes drug Ozempic cuts the risk of heart attack, stroke, and death by 23% compared to Eli Lilly's dulaglutide.
Novo Nordisk's Wegovy pill showed 16.6% weight loss in obesity trials, with over a third losing 20% or more. U.S. approval is pending, boosting shares by 6%.
Eli Lilly's orforglipron outperformed Novo Nordisk's Rybelsus in trials, showing greater weight loss and improved blood sugar control in type 2 diabetes patients, raising competitive concerns.
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
3.335 EUR
13.50 B EUR
38.82 B EUR
3.16 B
About Novo Nordisk A/S Class B
Sector
Industry
CEO
Maziar Mike Doustdar
Website
Headquarters
Bagsværd
Founded
1923
ISIN
DK0062498333
FIGI
BBG000DYN9V1
Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.
Related stocks
Novo Nordisk Setup – Is This the Pharma Sector’s Strongest Play?🚀 NVO "Novo Nordisk" – Wealth Strategy Map (Swing/Day Trade)
📈 Trade Plan (Bullish Setup)
Trend Confirmation: The bullish trend is supported by Dow Theory accumulation phase 📊.
Candle Signal: A Heikin Ashi Doji has formed, adding confluence to the setup.
Indicator Alert: LSMA (Least Squares Moving A
Market UpdateExited out GLXY position for 83% gain.
FED cuts rates as expected but market has this already priced in.
The AI basket is looking wobbly with price action i do not like.
Positions:
Long Novo Nordisk call option
Short Micron Technology put
Novo Nordisk trail results have been strong compared to
NVO currently consolidatedNVO is a relatively popular stock that entered into a steep downward channel. It arrived at a key support zone that must be throughly tested in order to break out of said downward channel.
A positive outlook is that it looks to be trading below fair value, but could be trading at $50 for next few m
NOVO is looking at a strong bullish bottoming outNYSE:NVO is looking at a strong bullish reversal and is likely to head higher after stochastic shows overbought AND long term stochastic shows clear confirmation of oversold crossover.
Price action shows a clear break out of the downtrend line and with the rounding bottom, the stock is likely to
NVO Down 65% From Highs - Falling Knife or Value Play? Current Setup
Price: $56.98
Position: Long since $48
Bullish Case
Recent Bounce: NVO rebounded strongly from support near $45, reclaiming multiple EMA bands and pushing above key levels ($54–$55).
RSI Momentum: RSI is trending upward from oversold territory, currently around 45.75—bullish momentu
Once in a Lifetime Opportunity and the Psychology behind itOnce in a Lifetime Opportunity and the Psychology behind it
There are moments in the market that happen so rarely , they feel almost mythical when they finally arrive. Novo Nordisk NYSE:NVO has just given us one of those moments.
If you’ve been following my work, you might remember my previo
NVO Bulls Load $60 Calls for 100%+ Weekly Gains!
# 🚀 NVO Weekly Options Trade Setup (08/24/2025)
**Consensus:** 🔥 Strong Bullish — All 5 AI models favor weekly calls!
**Market Context:** Low VIX (\~14.2) ✅, Heavy Call Flow (C/P 3.43) 📈, Institutional Volume ↑ 1.3x
---
lish on weekly horizon
* **Strategy:** Single‑leg weekly CALLs
* **Expiry:*
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
N
XS300255582
Novo Nordisk Finance (Netherlands) BV 3.625% 27-MAY-2037Yield to maturity
3.52%
Maturity date
May 27, 2037
N
XS282046075
Novo Nordisk Finance (Netherlands) BV 3.375% 21-MAY-2034Yield to maturity
3.26%
Maturity date
May 21, 2034
N
XS300255353
Novo Nordisk Finance (Netherlands) BV 3.125% 27-MAY-2033Yield to maturity
3.07%
Maturity date
May 27, 2033
N
XS282045567
Novo Nordisk Finance (Netherlands) BV 3.25% 21-JAN-2031Yield to maturity
2.88%
Maturity date
Jan 21, 2031
N
XS300255329
Novo Nordisk Finance (Netherlands) BV 2.875% 27-AUG-2030Yield to maturity
2.84%
Maturity date
Aug 27, 2030
XS244124704
Novo Nordisk Finance (Netherlands) BV 1.375% 31-MAR-2030Yield to maturity
2.72%
Maturity date
Mar 31, 2030
N
XS282045460
Novo Nordisk Finance (Netherlands) BV 3.125% 21-JAN-2029Yield to maturity
2.62%
Maturity date
Jan 21, 2029
N
XS300255299
Novo Nordisk Finance (Netherlands) BV 2.375% 27-MAY-2028Yield to maturity
2.57%
Maturity date
May 27, 2028
XS234803042
Novo Nordisk Finance (Netherlands) BV 0.125% 04-JUN-2028Yield to maturity
2.48%
Maturity date
Jun 4, 2028
N
XS282044994
Novo Nordisk Finance (Netherlands) BV 3.375% 21-MAY-2026Yield to maturity
2.39%
Maturity date
May 21, 2026
XS244933017
Novo Nordisk Finance (Netherlands) BV 1.125% 30-SEP-2027Yield to maturity
2.38%
Maturity date
Sep 30, 2027
See all NOV bonds
Curated watchlists where NOV is featured.
Frequently Asked Questions
The current price of NOV is 53.020 EUR — it has increased by 2.12% in the past 24 hours. Watch Novo Nordisk A/S Class B stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on SWB exchange Novo Nordisk A/S Class B stocks are traded under the ticker NOV.
NOV stock has risen by 11.37% compared to the previous week, the month change is a 5.23% rise, over the last year Novo Nordisk A/S Class B has showed a −55.33% decrease.
We've gathered analysts' opinions on Novo Nordisk A/S Class B future price: according to them, NOV price has a max estimate of 83.52 EUR and a min estimate of 40.09 EUR. Watch NOV chart and read a more detailed Novo Nordisk A/S Class B stock forecast: see what analysts think of Novo Nordisk A/S Class B and suggest that you do with its stocks.
NOV stock is 7.57% volatile and has beta coefficient of 1.53. Track Novo Nordisk A/S Class B stock price on the chart and check out the list of the most volatile stocks — is Novo Nordisk A/S Class B there?
Today Novo Nordisk A/S Class B has the market capitalization of 219.29 B, it has increased by 2.28% over the last week.
Yes, you can track Novo Nordisk A/S Class B financials in yearly and quarterly reports right on TradingView.
Novo Nordisk A/S Class B is going to release the next earnings report on Nov 5, 2025. Keep track of upcoming events with our Earnings Calendar.
NOV earnings for the last quarter are 0.80 EUR per share, whereas the estimation was 0.79 EUR resulting in a 0.46% surprise. The estimated earnings for the next quarter are 0.74 EUR per share. See more details about Novo Nordisk A/S Class B earnings.
Novo Nordisk A/S Class B revenue for the last quarter amounts to 10.28 B EUR, despite the estimated figure of 10.29 B EUR. In the next quarter, revenue is expected to reach 10.27 B EUR.
NOV net income for the last quarter is 3.54 B EUR, while the quarter before that showed 3.89 B EUR of net income which accounts for −8.86% change. Track more Novo Nordisk A/S Class B financial stats to get the full picture.
Novo Nordisk A/S Class B dividend yield was 1.83% in 2024, and payout ratio reached 50.28%. The year before the numbers were 1.35% and 50.35% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Sep 18, 2025, the company has 76.3 K employees. See our rating of the largest employees — is Novo Nordisk A/S Class B on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Novo Nordisk A/S Class B EBITDA is 21.50 B EUR, and current EBITDA margin is 50.95%. See more stats in Novo Nordisk A/S Class B financial statements.
Like other stocks, NOV shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Novo Nordisk A/S Class B stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Novo Nordisk A/S Class B technincal analysis shows the buy rating today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Novo Nordisk A/S Class B stock shows the sell signal. See more of Novo Nordisk A/S Class B technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.